Related Experiment Video
Updated: Apr 17, 2026
05:18
Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant
Published on: October 6, 2023
2.1K
Mapping Radiotherapy Resources for Prostate Cancer Trials in Nigeria: A STAMPEDE 2-Site Survey
Omolara Fatiregun1,2,3, Nwamaka Lasebikan4, Onyeanunam Ekeke5
1Department of Radiology and Clinical Oncology, Lagos State University College of Medicine, Ikeja, Nigeria.
JCO Global Oncology
|April 15, 2026
Summary
Nigeria shows readiness for advanced prostate cancer trials like STAMPEDE2, with growing radiotherapy infrastructure and clinician interest. Gaps in rural access and advanced imaging persist, but collaborative efforts are improving cancer care.
Area of Science:
- Oncology
- Clinical Trials
- Health Services Research
Background:
- The Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial established innovative treatment protocols.
- The STAMPEDE2 trial aims to further investigate advanced therapies for metastatic prostate cancer.
Purpose of the Study:
- To assess Nigeria's preparedness for the STAMPEDE2 trial.
- Evaluate current clinical practices, radiotherapy infrastructure, systemic therapy use, and imaging capabilities across Nigeria's six geopolitical zones.
Main Methods:
- A survey of 31 questions was distributed to oncologists via Google Forms from July to September 2024.
- Data collected on radiotherapy availability, systemic therapies, advanced imaging, and clinical trial readiness.
- Responses aggregated from 14 public and private cancer centers nationwide.
Main Results:
- 23 operational radiotherapy machines in 12 centers, with 19 more planned; predominantly in urban areas.
- 73% of centers have access to abiraterone and enzalutamide; one PET/CT facility exists.
- Clinicians expressed strong interest in trials, despite infrastructure gaps in rural areas and limited access to treatments like 177Lu-PSMA-617.
Conclusions:
- Nigeria demonstrates potential readiness for STAMPEDE2 and other clinical trials.
- Expanding radiotherapy infrastructure and clinician enthusiasm support collaborative research.
- Initiatives like the Cancer Health Fund are advancing equitable cancer care.
